SYHA-1813

N/A

Report date: 2026/05/22 20:01:29
NME

Base Information

Drug NameSYHA-1813
Drug Alias NameSYHA1813
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor antagonistsColony stimulating factor 1 receptor inhibitors
TargetsVascular endothelial growth factor receptorColony stimulating factor 1 receptor
Therapy Area/IndicationsBrain metastasesSolid tumoursSmall Cell Lung Carcinoma +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Runshi Pharmaceutical Technology Co LtdShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of SciencesShanghai Runshi Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsBrain metastasesSolid tumoursSmall Cell Lung Carcinoma +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A